MRx Pipeline

What is MRx Pipeline?

In its second year of publication, this quarterly publication offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast model addresses trends applicable across market segments. This industry leading report profiles:

  • Traditional and specialty drugs
  • Agents under the pharmacy and medical benefits
  • New molecular entities and biologics
  • Pertinent new and expanded indications for existing medications
  • Biosimilars

Last year marked a 21-year record high number of approvals as the United States Food and Drug Administration granted approvals to 46 novel drugs. Thus far in 2018, the FDA has approved 55 novel drugs, already surpassing 2017 approvals. As emerging therapeutics continue to grow and influence the clinical and financial landscape, the MRx Pipeline explores notable drug pipeline trends.

In the latest edition of MRx Pipeline, we provide in-depth clinical evaluations on many impactful classes in women’s health, immunology, oncology, neurology, and much more. This best-in-class publication provides insight on orphan drugs, biosimilars, and specialty medications. The drug pipeline climate will continue to evolve as it faces challenges and successes.  We highlighted 3 key trends from this edition:

  • Women’s health – larger focus is being placed on women’s health. Brexanolone was featured as a Deep Dive with a proposed indication of postpartum depression. An estimated 14% to 23% of pregnant women experience depression during pregnancy; 5% to 25% experience depression postpartum. The American College of Gynecology informs that postpartum care should extend into the “fourth trimester” – these stressful times following delivery, when a woman is recovering from childbirth, affected by changing hormones, and learning how to care for her newborn child.
  • Triple negative breast cancer (TNBC) – if approved sacituzumab govitecan will be the first drug to specifically be indicated for TNBC, which does not respond to typically used treatments for breast cancer (hormonal therapy, aromatase inhibitors, Herceptin® [trastuzumab]). TNBC accounts for 10-20% of all breast cancer cases.
  • Diabetes –sotagliflozin could become the first antidiabetic agent that blocks both sodium-glucose cotransporter-1 and -2 (SGLT1 and SGLT2), thereby, acting in both the gastrointestinal tract and the kidneys. It will also be the first oral medication to be used in combination with insulin for type 1 diabetes mellitus (T1DM). Although it can occur at any age, T1DM, previously referred to as juvenile diabetes, is the most common form of diabetes in childhood. .

The findings highlighted in the MRx Pipeline have been researched in detail with our internal team of clinical and analytics experts. Emerging therapeutics continue to grow and influence the clinical and financial landscape. Therefore, Magellan Rx Management has developed a systematic approach to identify products with significant clinical impact.

Click here to dig into MRx Pipeline.

By Maryam Tabatabai and Carole Kerzic

Related Articles

Leave a Reply

Your email address will not be published.